Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 18/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929259 | 0.83 | RORC (0.44) | SIGMAR1F2F10PRSS1PRSS2 | |
| SCHEMBL13952140 | 0.82 | TPSAB1 (0.50) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL13929264 | 0.79 | SIGMAR1 (0.47) | SIGMAR1F2F10PRSS1PRSS2 | |
| SCHEMBL13929260 | 0.73 | PKM (0.46) | SIGMAR1F2F10PRSS1PRSS2 | |
| SCHEMBL13951542 | 0.73 | SIGMAR1 (0.53) | SIGMAR1 | |
| SCHEMBL13929229 | 0.72 | OPRM1 (0.50) | SIGMAR1 | |
| SCHEMBL13929312 | 0.70 | RORC (0.47) | SIGMAR1 | |
| SCHEMBL4220531 | 0.70 | SIGMAR1 (0.54) | SIGMAR1 | |
| SCHEMBL29448589 | 0.69 | L3MBTL1 (0.64) | SIGMAR1 | |
| SCHEMBL4217001 | 0.69 | SIGMAR1 (0.57) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | ACKR3, CCR5, CCR7 | SIGMAR1 129/4885F2 4147/4885F10 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.